
GSK, Hengrui Pharma to develop up to 12 medicines across Respiratory, Immunology & Inflammation and Oncology
London: GSK plc has announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 innovative medicines, adding significant new growth opportunities to the company beyond 2031. The programmes were selected to …